JP2023515747A5 - - Google Patents

Info

Publication number
JP2023515747A5
JP2023515747A5 JP2022539336A JP2022539336A JP2023515747A5 JP 2023515747 A5 JP2023515747 A5 JP 2023515747A5 JP 2022539336 A JP2022539336 A JP 2022539336A JP 2022539336 A JP2022539336 A JP 2022539336A JP 2023515747 A5 JP2023515747 A5 JP 2023515747A5
Authority
JP
Japan
Prior art keywords
cell
cells
domain
immune
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022539336A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023515747A (ja
JP7884454B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/001079 external-priority patent/WO2021130535A2/en
Publication of JP2023515747A publication Critical patent/JP2023515747A/ja
Publication of JP2023515747A5 publication Critical patent/JP2023515747A5/ja
Application granted granted Critical
Publication of JP7884454B2 publication Critical patent/JP7884454B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022539336A 2019-12-28 2020-12-28 免疫調節分子を発現する細胞および免疫調節分子を発現するための系 Active JP7884454B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962954448P 2019-12-28 2019-12-28
US62/954,448 2019-12-28
PCT/IB2020/001079 WO2021130535A2 (en) 2019-12-28 2020-12-28 Cell expressing immune modulatory molecules and system for expressing immune modulatory molecules

Publications (3)

Publication Number Publication Date
JP2023515747A JP2023515747A (ja) 2023-04-14
JP2023515747A5 true JP2023515747A5 (cg-RX-API-DMAC7.html) 2024-01-11
JP7884454B2 JP7884454B2 (ja) 2026-07-03

Family

ID=75377831

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022539336A Active JP7884454B2 (ja) 2019-12-28 2020-12-28 免疫調節分子を発現する細胞および免疫調節分子を発現するための系

Country Status (5)

Country Link
US (1) US20230058519A1 (cg-RX-API-DMAC7.html)
EP (1) EP4081545A2 (cg-RX-API-DMAC7.html)
JP (1) JP7884454B2 (cg-RX-API-DMAC7.html)
CN (1) CN115103857B (cg-RX-API-DMAC7.html)
WO (1) WO2021130535A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119874940A (zh) * 2021-12-29 2025-04-25 上海细胞治疗集团股份有限公司 抗间皮素纳米抗体嵌合抗原受体及其应用
CN118206620A (zh) * 2022-12-09 2024-06-18 上海细胞治疗集团股份有限公司 一种多肽标签及其应用
CN119269786A (zh) * 2023-06-29 2025-01-07 上海细胞治疗集团股份有限公司 一种评估car产生细胞免疫应答的方法
WO2025209437A1 (zh) * 2024-04-02 2025-10-09 原启生物科技(上海)有限责任公司 经修饰的免疫细胞及其用途
WO2026152120A2 (en) 2025-01-13 2026-07-16 HCW Biologics, Inc. Chimeric polypeptides and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007042289A2 (en) * 2005-10-11 2007-04-19 Ablynx N.V. Nanobodies™ and polypeptides against egfr and igf-ir
WO2013110531A1 (en) * 2012-01-23 2013-08-01 Ablynx Nv Sequences directed against hepatocyte growth factor (hgf) and polypeptides comprising the same for the treatment of cancers and/or tumors
IL298125A (en) * 2013-02-26 2023-01-01 Memorial Sloan Kettering Cancer Center Preparations and methods for immunotherapy
WO2015197582A1 (en) * 2014-06-27 2015-12-30 Innate Pharma Monomeric multispecific antigen binding proteins
PT3393504T (pt) * 2015-12-22 2025-12-30 Novartis Ag Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
BR112018014585A2 (pt) * 2016-01-21 2018-12-11 Pfizer receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii
EP4086285A1 (en) * 2016-02-25 2022-11-09 Cell Medica Switzerland AG Binding members to pd-l1
US11541076B2 (en) * 2017-01-13 2023-01-03 Celdara Medical, Llc Chimeric antigen receptors targeting TIM-1
CA3099928A1 (en) * 2018-06-22 2019-12-26 The General Hospital Corporation Chimeric antigen receptors targeting cd37 and cd19
EP3930754A4 (en) 2019-02-27 2023-08-16 Zhejiang Nanomab Technology Center Co. Ltd. HIGH-THROUGHPUT SEQUENCE-BASED PROCEDURE FOR GENERATION OF CAMELID ANTIBODIES TO COVER WIDE EPITOPES WITH HIGH RESOLUTION

Similar Documents

Publication Publication Date Title
TWI809130B (zh) 嵌合跨膜蛋白及其用途
JP7433348B2 (ja) キメラポリペプチド及びそれらの細胞膜における局在を変更する方法
JP2021534835A5 (cg-RX-API-DMAC7.html)
JP2024023228A5 (cg-RX-API-DMAC7.html)
JP2022109975A5 (cg-RX-API-DMAC7.html)
US20240342283A1 (en) ROR1 CAR or ROR1 / CD19 Dual CAR T Cells for the Treatment of Tumors
JP2022541742A5 (cg-RX-API-DMAC7.html)
US12570958B2 (en) Single- and multi-chain chimeric antigen receptors
JP2019531328A5 (cg-RX-API-DMAC7.html)
CN113667021A (zh) 靶向b7h3的嵌合抗原受体及其应用
JP2021532742A5 (cg-RX-API-DMAC7.html)
JP2018526033A5 (cg-RX-API-DMAC7.html)
JP2017513818A5 (cg-RX-API-DMAC7.html)
RU2018122106A (ru) Буферы для стабилизации лентивирусных препаратов
JP2024511423A5 (cg-RX-API-DMAC7.html)
WO2020214928A1 (en) Bioassay for t-cell co-stimulatory proteins containing fc domains
JP2025503644A5 (cg-RX-API-DMAC7.html)
HK40013683A (en) Chimeric polypeptides and methods of altering their localisation in the cell membrane
WO2025081163A1 (en) Compositions for the treatment of cancer
CN117586411A (zh) 一种结合tnfr2和ccr8的双特异性抗体
HK40019125A (en) Chimeric polypeptides and methods of altering their localisation in the cell membrane
NZ791176A (en) Chimeric antigen receptors targeting bcma and methods of use thereof